Downstream, stacking cytokine blockers (e.g., IL-1 or IL-6 inhibitors) with steroids or other immunosuppressants increases serious-infection rates and requires screening and monitoring for hepatitis B reactivation with guideline-concordant antiviral prophylaxis in at-risk patients. This evidence concerns the gene PPIB and hepatitis A virus infection.